These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35379264)

  • 41. Phase 1-2 Study of Stereotactic Ablative Radiotherapy Including Regional Lymph Node Irradiation in Patients With High-Risk Prostate Cancer (SATURN): Early Toxicity and Quality of Life.
    Musunuru HB; D'Alimonte L; Davidson M; Ho L; Cheung P; Vesprini D; Liu S; Chu W; Chung H; Ravi A; Deabreu A; Zhang L; Commisso K; Loblaw A
    Int J Radiat Oncol Biol Phys; 2018 Dec; 102(5):1438-1447. PubMed ID: 30071295
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase 2 Multicenter Trial of Heterogeneous-dosing Stereotactic Body Radiotherapy for Low- and Intermediate-risk Prostate Cancer: 5-year Outcomes.
    Fuller DB; Falchook AD; Crabtree T; Kane BL; Medbery CA; Underhill K; Gray JR; Peddada A; Chen RC
    Eur Urol Oncol; 2018 Dec; 1(6):540-547. PubMed ID: 31158102
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Toxicity and quality of life report of a phase II study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancer.
    Boyer MJ; Papagikos MA; Kiteley R; Vujaskovic Z; Wu J; Lee WR
    Radiat Oncol; 2017 Jan; 12(1):14. PubMed ID: 28086825
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A pilot study of intensity modulated radiation therapy with hypofractionated stereotactic body radiation therapy (SBRT) boost in the treatment of intermediate- to high-risk prostate cancer.
    Oermann EK; Slack RS; Hanscom HN; Lei S; Suy S; Park HU; Kim JS; Sherer BA; Collins BT; Satinsky AN; Harter KW; Batipps GP; Constantinople NL; Dejter SW; Maxted WC; Regan JB; Pahira JJ; McGeagh KG; Jha RC; Dawson NA; Dritschilo A; Lynch JH; Collins SP
    Technol Cancer Res Treat; 2010 Oct; 9(5):453-62. PubMed ID: 20815416
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.
    King CR; Brooks JD; Gill H; Pawlicki T; Cotrutz C; Presti JC
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1043-8. PubMed ID: 18755555
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Stereotactic body radiation therapy for Japanese patients with localized prostate cancer: 2-year results and predictive factors for acute genitourinary toxicities.
    Ito M; Yoshioka Y; Takase Y; Suzuki J; Matsunaga T; Takahashi H; Takeuchi A; Adachi S; Abe S; Oshima Y; Ohtakara K; Suzuki K; Okuda T
    Jpn J Clin Oncol; 2021 Aug; 51(8):1253-1260. PubMed ID: 34128053
    [TBL] [Abstract][Full Text] [Related]  

  • 47. First Australian experience of treating localised prostate cancer patients with CyberKnife stereotactic radiotherapy: early PSA response, acute toxicity and quality of life.
    Dixit A; Tang C; Bydder S; Kedda MA; Vosikova E; Bharat C; Gill S
    J Med Radiat Sci; 2017 Sep; 64(3):180-187. PubMed ID: 28271639
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interim Results of a Prospective Prostate-Specific Membrane Antigen-Directed Focal Stereotactic Reirradiation Trial for Locally Recurrent Prostate Cancer.
    Bergamin S; Eade T; Kneebone A; Booth J; Hsiao E; Schembri GP; Szymura K; Le A; Kwong C; Brown C; Hunter J; Hruby G
    Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1172-1178. PubMed ID: 32659332
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Linac-based stereotactic body radiation therapy for low and intermediate-risk prostate cancer : Long-term results and factors predictive for outcome and toxicity.
    Franzese C; Badalamenti M; Di Brina L; D'Agostino G; Franceschini D; Comito T; Clerici E; Navarria P; Reggiori G; Mancosu P; Tomatis S; Scorsetti M
    Strahlenther Onkol; 2020 Jul; 196(7):608-616. PubMed ID: 32303782
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life After Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate Cancer.
    Bryant C; Smith TL; Henderson RH; Hoppe BS; Mendenhall WM; Nichols RC; Morris CG; Williams CR; Su Z; Li Z; Lee D; Mendenhall NP
    Int J Radiat Oncol Biol Phys; 2016 May; 95(1):422-434. PubMed ID: 27084658
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Stereotactic Body Radiotherapy for Clinically Localized Prostate Cancer: Toxicity and Biochemical Disease-Free Outcomes from a Multi-Institutional Patient Registry.
    Davis J; Sharma S; Shumway R; Perry D; Bydder S; Simpson CK; D'Ambrosio D
    Cureus; 2015 Dec; 7(12):e395. PubMed ID: 26798571
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Stereotactic body radiation therapy for low and intermediate risk prostate cancer-Results from a multi-institutional clinical trial.
    Hannan R; Tumati V; Xie XJ; Cho LC; Kavanagh BD; Brindle J; Raben D; Nanda A; Cooley S; Kim DWN; Pistenmaa D; Lotan Y; Timmerman R
    Eur J Cancer; 2016 May; 59():142-151. PubMed ID: 27035363
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Stereotactic Body Radiotherapy Using CyberKnife® for Localized Low- and Intermediate-risk Prostate Cancer: Initial Report on a Phase I/II Trial.
    Nakamura R; Hirata T; Suzuki O; Otani K; Kai N; Hatano K; Fujita K; Uemura M; Imamura R; Tanaka K; Yoshioka Y; Nonomura N; Ogawa K
    Anticancer Res; 2020 Apr; 40(4):2053-2057. PubMed ID: 32234896
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Stereotactic body radiotherapy as a boost after external beam radiotherapy for high-risk prostate cancer patients.
    Turna M; Akboru H; Ermis E; Oskeroglu S; Dincer S; Altin S
    Indian J Cancer; 2021; 58(4):518-524. PubMed ID: 33402584
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Prospective Study of Stereotactic Body Radiotherapy (SBRT) with Concomitant Whole-Pelvic Radiotherapy (WPRT) for High-Risk Localized Prostate Cancer Patients Using 1.5 Tesla Magnetic Resonance Guidance: The Preliminary Clinical Outcome.
    Poon DMC; Yuan J; Yang B; Wong OL; Chiu ST; Chiu G; Cheung KY; Yu SK; Yung RWH
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884553
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prospective Randomized Phase II Study of Stereotactic Body Radiotherapy (SBRT) vs. Conventional Fractionated Radiotherapy (CFRT) for Chinese Patients with Early-Stage Localized Prostate Cancer.
    Poon DMC; Lam D; Wong KCW; Chu CM; Cheung M; Mo F; Suen J; Ng CF; Chan ATC
    Curr Oncol; 2021 Dec; 29(1):27-37. PubMed ID: 35049677
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dose-volume analysis and the temporal nature of toxicity with stereotactic body radiation therapy for prostate cancer.
    Seymour ZA; Chang AJ; Zhang L; Kirby N; Descovich M; Roach M; Hsu IC; Gottschalk AR
    Pract Radiat Oncol; 2015; 5(5):e465-e472. PubMed ID: 25795252
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High-quality Linac-based Stereotactic Body Radiation Therapy with Flattening Filter Free Beams and Volumetric Modulated Arc Therapy for Low-Intermediate Risk Prostate Cancer. A Mono-institutional Experience with 90 Patients.
    D'Agostino G; Franzese C; De Rose F; Franceschini D; Comito T; Villa E; Alongi F; Liardo R; Tomatis S; Navarria P; Mancosu P; Reggiori G; Cozzi L; Scorsetti M
    Clin Oncol (R Coll Radiol); 2016 Dec; 28(12):e173-e178. PubMed ID: 27389021
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Five-year outcomes of stereotactic body radiation therapy (SBRT) for prostate cancer: the largest experience in China.
    Zhao X; Ye Y; Yu H; Jiang L; Cheng C; Guo X; Ju X; Zhu X; Zhang H
    J Cancer Res Clin Oncol; 2021 Dec; 147(12):3557-3564. PubMed ID: 34528135
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.
    Pederson AW; Fricano J; Correa D; Pelizzari CA; Liauw SL
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):235-41. PubMed ID: 21163587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.